PROCEPT BioRobotics (PRCT) is back in focus after Aquablation therapy received a strong recommendation in updated European Association of Urology guidelines for treating benign prostatic hyperplasia. This represents a shift that could influence future procedure choices.

Despite the guideline upgrade and HYDROS rollout, the current share price of $26.02 sits against a 1 year total shareholder return of a 57.27% loss and a 3 year total shareholder return of an 8.35% loss. This suggests recent momentum has been weak even as clinical recognition builds.

If this kind of medical robotics story interests you, it may be worth broadening your search and checking out 32 robotics and automation stocks

With Aquablation now strongly backed in European guidelines, yet PROCEPT BioRobotics still carrying steep 1 year and 3 year losses, is the market overlooking the story here or already pricing in the company’s next phase of growth?

Most Popular Narrative: 19.9% Undervalued

Compared with the last close at $26.02, the most followed narrative points to a fair value of $32.50, suggesting investors are not fully aligning with that view yet.

The analyst price target for PROCEPT BioRobotics has been revised from about $50.73 to $32.50 as analysts factor in recent Q4 misses, reduced 2026 guidance, questions around market penetration for Aquablation, and concerns about execution on sales and discounting changes in a competitive BPH market.

Street research around PROCEPT BioRobotics has shifted toward a more cautious stance, with several firms cutting price targets and reassessing expectations after Q4 results and lower 2026 guidance. Even so, there are still pockets of optimism tied to the Aquablation opportunity and management's long term vision.

Want to see how cautious guidance, ambitious margin goals, and revised revenue assumptions still add up to a higher fair value? The narrative spells out the earnings path, the implied profitability shift, and the valuation multiple that has to hold for $32.50 to make sense.

Result: Fair Value of $32.50 (UNDERVALUED)

However, you also need to weigh the risk that PROCEPT remains dependent on HYDROS and Aquablation while still running operating losses with no clear path to near term profitability.

Next Steps

With the mix of concern and optimism running through this story, take a moment to check the numbers yourself and decide how you see the balance of risk and reward. Then round out your view by weighing up the 1 key reward and 2 important warning signs

Looking for more investment ideas?

Do not stop your research with a single stock. Broaden your watchlist using focused stock ideas that can help you spot opportunities others might overlook.

• Zero in on potential bargains by scanning companies that stand out on value and quality via the 55 high quality undervalued stocks.
• Prioritise stability by reviewing the 74 resilient stocks with low risk scores and see which businesses score well on resilience and downside protection.
• Get ahead of the crowd by checking the screener containing 26 high quality undiscovered gems and see which underfollowed names still show strong fundamentals.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.